Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Testing: To ensure label accuracy, we prioritized products that are tested throughout the manufacturing process, ideally by third-party labs and organizations, like NSF International
In SELECT, Wegovy reduced the risk of MACE by 20% compared to the placebo group
Lilly has submitted for FDA approval for obesity, with a T2D submission expected later in 2026
Proposed mechanisms of Tesamorelin: Activates GHRH receptors Increases endogenous GH release Elevates IGF-1 production Promotes lipolysis Reduces visceral adipose tissue Why Tesamorelin is unique: Unlike most weight-loss therapies, Tesamorelin appears particularly effective at reducing visceral fat the deep abdominal fat surrounding internal organs that is strongly associated with insulin resistance, cardiovascular disease, and metabolic syndrome
US$ 25.24
US$ 25.48
US$ 27.44
US$ 20.64
US$ 24.52
US$ 21.67
US$ 25.79
US$ 24.45
US$ 25.57
US$ 25.19
